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Background: Despite advances in heart transplantation and mechanical circulatory
support, mortality among transplant candidates remains high. Better ways are
needed to ensure the survival of transplant candidates both inside and outside the
hospital.
Methods: In a prospective, multicenter clinical trial conducted at 24 centers in the
United States, 280 transplant candidates (232 men, 48 women; median age, 55
years; range, 11-72 years) unresponsive to inotropic drugs, intra-aortic balloon
counterpulsation, or both, were treated with the HeartMate Vented Electric Left
Ventricular Assist System (VE LVAS). A cohort of 48 patients (40 men, 8 women;
median age, 50 years; range, 21-67 years) not supported with an LVAS served as a
historical control group. Outcomes were measured in terms of laboratory data
(hemodynamic, hematologic, and biochemical), adverse events, New York Heart
Association functional class, and survival.
Results: The VE LVAS–treated and non–VE LVAS–treated (control) groups were
similar in terms of age, sex, and distribution of patients by diagnosis (ischemic car-
diomyopathy, idiopathic cardiomyopathy, and subacute myocardial infarction). VE
LVAS support lasted an average of 112 days (range, < 1-691 days), with 54 patients
supported for > 180 days. Mean VE LVAS flow (expressed as pump index) through-
out support was 2.8 L · min–1 · m–2. Median total bilirubin values decreased from
1.2 mg/dL at baseline to 0.7 mg/dL (P = .0001); median creatinine values decreased
from 1.5 mg/dL at baseline to 1.1 mg/dL (P = .0001). VE LVAS–related adverse
events included bleeding in 31 patients (11%), infection in 113 (40%), neurologic
dysfunction in 14 (5%), and thromboembolic events in 17 (6%). A total of 160
(58%) patients were enrolled in a hospital release program. Twenty-nine percent of
the VE LVAS-treated patients (82/280) died before receiving a transplant, compared
with 67% of controls (32/48) (P < .001). Conversely, 71% of the VE LVAS–treated
patients (198/280) survived: 67% (188/280) ultimately received a heart transplant,
and 4% (10/280) had the device removed electively. One-year post-transplant sur-
vival of VE LVAS–treated patients was significantly better than that of controls
(84% [158/188] vs 63% [10/16]; log rank analysis P = .0197).
Conclusion: The HeartMate VE LVAS provides adequate hemodynamic support,
has an acceptably low incidence of adverse effects, and improves survival in heart
transplant candidates both inside and outside the hospital. The studies of the
HeartMate LVAS (both pneumatic and electric) for Food and Drug Administration
approval are the only studies with a valid control group to show a survival benefit
for cardiac transplantation. 
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The use of ventricular assist systems has dra-matically improved the functional status andquality of life of patients with end-stage heartdisease awaiting heart transplantation whileat the same time reducing their mortality.1-6In fact, many clinical developments in the
area of mechanical circulatory support have stemmed from
progress in its use in heart transplantation candidates.7,8
However, because of the constant shortage of donor hearts,
heart transplantation has little direct statistical impact on the
growing population of patients with end-stage heart disease.
Research has continued to support not only the testing of
mechanical devices as bridges to transplantation but also the
development of long-term devices as alternatives to heart
transplantation. One thrust of this research was to develop
systems that would permit transplant candidates to be dis-
charged from the hospital, a long-term goal in the develop-
ment of implantable circulatory assist systems that may
ultimately provide “destination therapy” for the many
patients for whom heart transplantation is not an option.
Since 1986, more than 2700 patients worldwide have
been treated with HeartMate Left Ventricular Assist
Systems (LVAS). During this period, two multicenter clini-
cal trials have evaluated the safety and effectiveness of the
HeartMate technology as a bridge to transplantation. The
first of these trials evaluated the first-generation HeartMate
Implantable Pneumatic LVAS (IP LVAS) (Thermo Cardio-
systems, Inc, Woburn, Mass), and until now it had been the
only trial to compare an LVAS-treated group with a control
group.2,3
The second of the two multicenter clinical trials evalu-
ated the safety and efficacy of the second-generation
HeartMate Vented Electric LVAS (VE LVAS) (Thermo
Cardiosystems, Inc) in transplant candidates both inside and
outside the hospital. After extensive clinical evaluation, the
HeartMate VE LVAS finally received approval from the
Food and Drug Administration in September 1998 for use
as a mechanical circulatory support bridge to cardiac trans-
plantation, both inside the hospital and at home, in patients
at imminent risk of death from heart failure. Here, we report
the results of the VE LVAS multicenter trial.
Materials and Methods
Device 
The HeartMate VE LVAS consists of a pusher-plate blood pump
driven by an integral electric motor with a percutaneous power and
control circuit. The titanium alloy housing contains a flexible
diaphragm that divides the interior into two chambers: one con-
tains a textured blood path; the other houses a motor that is vented
to the atmosphere via the percutaneous drive line. All blood-
contacting surfaces, except the valves, are textured. The textured
polyurethane diaphragm and the sintered titanium surfaces are
engineered to trap and firmly anchor blood components, thus cre-
ating a stable biologic neointima similar to the lining of natural
blood vessels. Once formed, the neointima prevents blood from
contacting artificial materials. In addition, the assembled pump
contains 25-mm porcine xenograft valves at both the inflow and
outflow conduits. The carefully designed blood path and internal
flow characteristics of the VE LVAS reduce activation of coagula-
tion and minimize the need for anticoagulants.
Like the HeartMate IP LVAS, the VE LVAS is implanted
through a median sternotomy incision extending to just above the
umbilicus; this is done with the use of standard cardiopulmonary
bypass. An inflow cannula is placed in the left ventricular apex, and
an outflow graft is passed over the diaphragm to the ascending
aorta, where it is anastomosed end to side at the aortic root. The
pump body resides below the diaphragm in either an intraperitoneal
position or preperitoneal pocket. A detailed description of the
device’s orientation and implantation protocol has been published.1
The HeartMate VE LVAS operates in one of two modes: (1) an
asynchronous, fixed-rate mode programmable to a pump rate of 50
to 120 beats/min or (2) an automatic rate mode with a pump rate
responsive to the pump fill rate. Once the patient’s recovery from
the implantation procedure is complete, wearable external compo-
nents including batteries and a system controller allow the patient
to be fully ambulatory and to participate in an exercise rehabilita-
tion program (Figure 1).
Because the textured blood-contacting surfaces and biopros-
thetic valves of the VE LVAS drastically reduce the need for anti-
coagulation treatment,9 minimal or no anticoagulant therapy is
needed. Most patients (77%) received antiplatelet treatment only
in the form of aspirin (80-325 mg once daily) and/or dipyridamole
(75 mg 3 times daily). However, 23% of patients received at least
1 dose of warfarin (Coumadin).
Patient Population
Between February 1996 and September 1998, 280 nonrandomized
heart transplant candidates were enrolled at 24 medical centers
within the United States for treatment with the HeartMate VE
LVAS as a bridge to transplantation. The group consisted of 232
men (83%) and 48 women (17%) and had a median age of 55
years (range, 11-72 years).
For comparison, a historical, nonrandomized control group of
48 patients from the IP HeartMate study was used.2 These 48
patients were enrolled at 14 of the 24 clinical centers mentioned
above between April 1988 and April 1994. This group consisted of
40 men (83%) and 8 women (17%) (median age, 50 years; range,
21-67 years) who met all the criteria for device implantation but
did not undergo implantation of a left ventricular assist device at
the institutions participating in this study because the device was
simply unavailable (before Food and Drug Administration
approval, the maker’s production capabilities were limited) or
because the family refused treatment.
All patients in both groups had to meet specific selection crite-
ria (Table 1). Informed consent and data from all patients were
obtained in compliance with protocols approved by each institu-
tion’s institutional review board. In addition, all patients in the
treatment group signed an informed consent form that specifically
addressed the implantation and hospital discharge (release pro-
gram) phases of the trial.
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Laboratory Data Collection
Laboratory data (hemodynamic, hematologic, and biochemical)
were obtained from all treated and control patients for the duration
of the study.
Hemodynamic data. Hemodynamic data included mean pul-
monary capillary wedge pressure (mm Hg), mean systolic blood
pressure (mm Hg), and cardiac index (L · min–1 · m–2). These data
were collected from patients at baseline (study entry), when all were
already receiving maximal medical and more than half (166/328)
were receiving intra-aortic balloon pump support therapy. After that,
systolic blood pressure was recorded weekly throughout the study.
Device performance data (ie, pump rate, pump stroke volume, pump
flow, and operating mode) were recorded daily for 14 days after VE
LVAS implantation and then weekly thereafter.
Hematologic data. Hematocrit, hemoglobin, platelet count,
leukocyte count, plasma free hemoglobin, prothrombin time, and
activated partial thromboplastin time were measured at baseline
and weekly thereafter.
Biochemical data. Blood urea nitrogen, serum creatinine, total
bilirubin, aspartate aminotransferase, and alanine aminotrans-
ferase were measured at baseline and weekly thereafter.
Adverse Events
Adverse events (as defined below) were monitored throughout the
study and were recorded as they occurred. Adverse events
included bleeding, hemolysis, infection, right heart failure, renal
dysfunction, hepatic dysfunction, neurologic dysfunction, pul-
monary dysfunction, thromboembolic events, device malfunction,
mechanical failure, and death. According to our definitions of
adverse events, each adverse event was judged by the principal
investigator to be either device- or patient-related. An adverse
event was considered device-related if it was related or attributable
to the malfunction or failure of the device or if its new onset could
not be attributed to another source.
Bleeding. Bleeding was defined as blood loss serious enough
to necessitate returning the patients to the operating room or to
cause death (eg, cardiac tamponade).
Hemolysis. Hemolysis was defined as 2 consecutive measure-
ments of hemoglobin values greater than 40 mg/dL.
Infection. Systemic infection was defined as infection detected
by positive blood, urine, sputum, or tissue cultures in association
with an elevated white blood cell count (≥12,500/mL), fever
(≥38.1°C), and treatment with antimicrobial agents. Additionally,
data were collected on drive-line infection, which was defined as
any infection that (1) was detected by the positive cultures
obtained from the drive-line exit site and (2) required treatment
with antimicrobial agents.
Right heart failure. Right heart failure was defined as the
inability of the heart to provide sufficient flow from the right ven-
tricle to the left ventricle, thus necessitating the use of a right ven-
tricular assist device.
Renal dysfunction. Renal dysfunction was defined as a serum
creatinine value of 2.2 mg/dL or more or a blood urea nitrogen
value of 50 mg/dL or more.
Hepatic dysfunction. Hepatic dysfunction was defined as a
total bilirubin value of 1.4 mg/dL or more or as either an aspartate
aminotransferase or alanine aminotransferase value of 50 U/L or
more in cases in which the elevation in bilirubin level was not due
to hemolysis.
Neurologic dysfunction. Neurologic dysfunction was defined
as any central nervous system or gross neuromuscular disorder
identified by standard neurologic examination of reflexes, speech,
vision, and so on.
Pulmonary dysfunction. Pulmonary dysfunction was defined
as a forced expiratory volume in 1 second of less than 45%. It was
measured after VE LVAS implantation only if the patient had
symptoms.
Thromboembolic event. A thromboembolic event was defined
by clinical symptoms of stroke or by sudden neurologic, pul-
monary, renal, hepatic, or peripheral vascular changes.
Device malfunction. A device malfunction was defined as any
instance in which any component of the system failed to perform
in the intended manner.
Mechanical failure. Mechanical failure was defined as the
inability of the VE LVAS, including its backup components, to
provide circulatory support.
Figure 1. The HeartMate VE LVAS.
TABLE 1. Study inclusion and exclusion criteria
Inclusion criteria
Approved (listed) transplant candidate (required)
Current inotropic therapy (required)
Intra-aortic balloon pump support (if possible)
Left atrial pressure or pulmonary capillary wedge pressure ≥ 20
mm Hg combined with either:
Systolic blood pressure ≤ 80 mm Hg or
Cardiac index ≤ 2.0 L · min–1 · m–2
Exclusion criteria
Body surface area < 1.5 m2
Any medical condition that would exclude the patient from
transplantation
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Functional Status
New York Heart Association (NYHA) functional status was evalu-
ated in all patients at baseline, on enrollment in the release pro-
gram, weekly during release, and after transplantation.
Evaluation of Patients Outside the Hospital (Release
Program)
The performance of the VE LVAS outside the hospital was also
evaluated. Release from the hospital (the “release program”) was
limited to those patients who qualified to await transplantation
outside of the hospital (see Table 2 for inclusion criteria).
All patients in the release program received backup and emer-
gency equipment and training in its use. Before release, each
patient also had to identify a companion who could assist the
patient in an emergency. Both patient and companion were then
trained in the proper setup and operation of the VE LVAS and in
emergency response procedures, and both were required to
demonstrate competency in the use of the supplied equipment
before release.
Under the release program, patients were released from the
hospital in a controlled, stepwise fashion. In general, they were
initially allowed to leave the hospital for short day trips; they could
then progress over time to full outpatient status (ie, they were
allowed to live at home or outside the hospital while awaiting a
transplant). All patients were required to return to the hospital
weekly for evaluation (ie, NYHA functional status and hemody-
namic, hematologic, and biochemical tests) and to report on their
activities while away from the hospital. All adverse events (antic-
ipated and unanticipated) that occurred away from the hospital
were recorded.
Survival Outcomes
Survival to transplantation and survival after transplantation of
treated and control patients were recorded.
Statistical Methods
Comparisons between VE LVAS–treated patients and controls
were performed by the Fisher exact test or the Student unpaired t
tests as appropriate. Changes in hemodynamic and biochemical
data from baseline to final measurement before transplantation or
death were analyzed by the Student paired t test. (Baseline and
final values were expressed as either mean ± SD or median and
range.) Probability was 2-tailed. Survival to transplantation and
survival after transplantation were analyzed by the Kaplan-Meier
product limit method. Differences in survival distributions
between VE LVAS–treated and control groups were analyzed by
means of a log-rank test. Variables for predicting survival to trans-
plantation were identified by the Cox proportional hazards model
and entered stepwise into the model. All variables selected for the
hazards model were visually assessed by log-log curves to ensure
compliance with the proportional hazards assumption.
Results
Patient Demographics
The VE LVAS–treated and control groups were similar in
terms of age, sex, and distribution of patients by diagnosis
(ischemic cardiomyopathy, idiopathic cardiomyopathy, and
subacute myocardial infarction) (Table 3).
Median Waiting Time to Transplantation
In the control group, the median waiting time from study
entry to transplantation was 4 days and in the VE LVAS–
treated group, 105.5 days (P < .0001).
Average Length of VE LVAS Support
VE LVAS support lasted an average of 112 days (range, <1-
691 days), with 54 patients supported for more than 180
days.
TABLE 2. Inclusion and exclusion criteria for participation
of VE LVAS–treated patients in the release program
Inclusion criteria
LVAS implanted for ≥ 14 days
NYHA class I or II
Left ventricular contractility sufficient to open the aortic valve
while LVAS operating at 50 beats/min
Exclusion criteria
Residence > 2 hours from hospital
Companion not available
No desire by patient or companion to participate in release
program
Uncertainty regarding patient’s or companion’s ability to manage
equipment
LVAS malfunction that affects patient’s safety or device
effectiveness
Patient’s need for medications that require hospitalization
Inadequate backup equipment
Potential availability of a donor heart
Unresolved adverse event that may threaten patient’s safety
(eg, active systemic infection)
Known medical condition that might jeopardize patient’s safety
(eg, severe arrhythmia)
TABLE 3. Patient demographics at baseline
VE LVAS–
treated Historical
patients controls
Variable (n = 280) (n = 48) P value
Median age, y (range) 55 (11-72) 50 (21-67) .379
Sex
Male (%) 232 (83%) 40 (83%)
Female (%) 48 (17%) 8 (17%) 1.000
Diagnosis
Ischemic cardiomyopathy (%) 129 (46%) 28 (58%)
Idiopathic cardiomyopathy (%) 131 (47%) 17 (35%) .285
Myocardial infarction (%) 20 (7%) 3 (6%)
Mean body surface area, 1.97 1.92 .128
m2 (range) (1.45-2.75) (1.55-2.30)
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Baseline Hemodynamic Data
The hemodynamic indices of treated and control patients at
baseline and after pharmacologic and intra-aortic balloon
pump therapy were evaluated and compared (Table 4).
Whereas no difference was found in the pulmonary capil-
lary wedge pressure, the mean systolic blood pressure and
mean cardiac index were significantly lower in the VE
LVAS–treated group than in the control group (P < .0001).
Hemodynamic Performance of the VE LVAS
Mean VE LVAS flow (expressed as pump index) was 2.8 ±
0.5 L · min–1 · m–2. The average pump index 1 month after
implant (2.85 ± 0.52 L · min–1 · m–2) was significantly
greater than the average cardiac index recorded at baseline
(1.68 ± 0.43 L · min–1 · m–2) (P = .0001).
Hematologic Data
No significant changes were found in levels of plasma free
hemoglobin before (8.5 ± 12.8 mg/dL) or during LVAS sup-
port (7.4 ± 16.0 mg/dL) or in other hematologic variables
(Table 5).
Hepatic and Renal Function Data
No significant differences in renal and hepatic function at
baseline were observed between the treated and control
groups (Table 6). However, renal and hepatic function in VE
LVAS–treated patients significantly improved between
baseline and final measurement before LVAS removal (P =
.0001) (Table 7). Blood urea nitrogen levels fell from 32 to
20 mg/dL (P = .0001). Creatinine values fell from 1.5 to 1.1
mg/dL (P = .0001). Total bilirubin values fell from 1.2 to
0.7 mg/dL (P = .0001). Alanine aminotransferase values fell
from 47 to 26 IU (P = .0001). Aspartate aminotransferase
values fell from 42 to 32 IU (P = .0001).
Adverse Events
Adverse events in VE LVAS–treated patients throughout the
study were recorded (Table 8).
Bleeding of any kind was noted in a total of 133 treated
patients (48%). Bleeding arising directly from the device
itself (including its connectors or grafts) or from the abdom-
inal implant site was identified in 31 patients (11%).
Eighty-three percent of the treated patients (111/133) who
had bleeding events bled perioperatively (within 5 days of
implant, reimplant, or explant).
Infections occurred in 125 (45%) patients, most fre-
quently at the drive-line exit site (90/125; 72%).
After device implantation, renal and hepatic dysfunction
(detected by at least 1 abnormal laboratory test) was present
TABLE 4. Baseline hemodynamic data*
VE LVAS-
treated Historical
patients controls
Variable (n = 280) (n = 48) P value
IABP support (%) 137 (49%) 29 (60%) .160
PCWP (mm Hg) 27.4 ± 6.6 27.8 ± 7.6 .737
Systolic blood pressure (mm Hg) 75.5 ± 9.7 86.1 ± 15.4 <.0001
Cardiac index (L · min–1 · m–2) 1.67 ± 0.41 2.03 ± 0.72 <.0001
IABP, Intra-aortic balloon pump; PCWP, pulmonary capillary wedge pres-
sure.
*Variables expressed as mean ± standard deviation.
TABLE 5. Hematologic data
Baseline During VE LVAS use
Variable (mean ± SD) (mean ± SD)
Hemoglobin (g/dL) 11.1 ± 2.3 10.0 ± 3.8
Hematocrit (%) 32.4 ± 6.0 32.2 ± 5.5
WBC (×103) 11.2 ± 4.9 9.2 ± 5.0
Platelet count (×103) 198.1 ± 94.3 259.3 ± 107.0
Prothrombin time (s) 15.4 ± 6.3 14.5 ± 4.4
Partial thromboplastin time (s) 51.2 ± 29.6 32.8 ± 15.5
Plasma free hemoglobin (mg/dL) 8.5 ± 12.8 7.4 ± 16.0
SD, Standard deviation; WBC, white blood cell count.
TABLE 6. Baseline renal and hepatic function*
VE LVAS-
treated Historical
patients controls
Variable (n = 280) (n = 48) P value
Blood urea nitrogen (mg/dL) 38.9 ± 23.2 37.5 ± 20.1 .697
Creatinine (mg/dL) 1.72 ± 1.02 1.58 ± 0.54 .325
Total bilirubin (mg/dL) 2.08 ± 2.91 1.69 ± 1.29 .373
*Variables expressed as mean ± SD.
TABLE 7. Improvement in renal and hepatic function from
baseline to final measurement*
Final
value
before
transplant or
Variable No. Baseline death P value
BUN (mg/dL) 271 32 (7-135) 20 (6-174) .0001
Creatinine (mg/dL) 271 1.5 (0.4-8.9) 1.1 (0.1-6.2) .0001
Total bilirubin (mg/dL) 240 1.2 (0.2-23.3) 0.7 (0.2-59.8) .0001
ALA (IU) 219 47 (4-3612) 26 (2-1910) .0001
AST (IU) 237 42 (9-5146) 32 (6-1008) .0001
BUN, Blood urea nitrogen; ALA, alanine aminotransferase; AST, aspartate
aminotransferase.
*Variables expressed as median (range). Data were analyzed by the
Student paired t test.
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in 158 (56%) patients and 263 (94%) patients, respectively. Of
these patients, 94 (59%) had entered the trial with renal dys-
function and 174 (66%) had entered with hepatic dysfunction.
Right heart failure occurred in 31 (11%) patients, 10 of
whom subsequently underwent transplantation and 21 of
whom died before transplantation.
Neurologic complications occurred in 75 (27%) patients
but were deemed device-related in only 14 (5%). Other neu-
rologic complications included metabolic encephalopathy,
seizures, confusion, and syncope that were attributed to a
cause other than the device. Thromboembolic events occurred
in 34 (12%) patients. In 17 (6%) of these, the event could not
be attributed to another cause and was deemed device-related.
Mechanical failure occurred in 3 (1%) patients and in all
3 instances resulted in death. The mechanical failures were
due to 2 disconnections of the outflow assembly from the
pump body and 1 pump diaphragm failure. Both of the fail-
ure modes have been analyzed and pump improvements
implemented. In addition, 435 confirmed device malfunc-
tions occurred during the study period. Most of these
(375/435; 86%) were malfunctions of external accessories,
including the controller, batteries, battery clips, power base
unit cable, and display module (external component mal-
function rate = 1.192 per 100 patient-days). The controller
accounted for more than half (195/375; 52%) of the exter-
nal component malfunctions.
During the present study, 25 (9%) of the 280 treated
patients needed to use the backup components (hand pump
or IP console) because of controller or cable malfunction
(11/25 patients) or pump stoppage (14/25 patients). The
pump stoppages were largely due to either electrostatic dis-
charge or component malfunctions within the pump com-
mutator. Fixes to both of these malfunctions have been
implemented. Of the 25 patients who used the backup com-
ponents, 18 (72%) survived to transplantation.
Experience Outside the Hospital (Release Program)
Patient outcomes. Of 228 VE LVAS–treated patients eligi-
ble to participate in the release program phase of this study,
160 (70%) actually did participate. Ultimately, only 115 of
the 160 released patients achieved full outpatient status. The
remaining 45 patients only left the hospital for day trips,
overnight trips, and 3-day releases from the hospital and did
not reach full outpatient status for a variety of reasons (eg,
they were receiving transplants, the study investigators were
cautious about allowing them outside the hospital, or the
patients chose not to leave). The 160 patients in the release
program accumulated 33.9 patient-years away from the
hospital. The median length of outpatient stay was 82 days
(range, 3–660 days). Of the 160 patients, 138 (86%) ulti-
mately received a transplant, 10 (6%) elected to have the
device removed without a subsequent transplant, and 12
(8%) died while awaiting a transplant.
Improvement in NYHA functional class. Of the 160 VE
LVAS–treated patients enrolled in the release program, 153
(96%) had NYHA class IV function at baseline and 7 (4%)
belonged to classes I-III. By the time these patients quali-
fied for outpatient treatment, 91 (57%) belonged to NYHA
class II and 69 (43%) belonged to NYHA class I. This
change in NYHA functional class was significant (P < .001)
and indicated that the improvement in functional class was
due to mechanical circulatory support (Table 9).
Survival Outcomes
Pretransplantation survival. The VE LVAS underwent 86
patient-years of use during the present clinical trial. A total
of 188 (67%) patients were successfully bridged to trans-
plantation, 10 (4%) patients elected to have the device
removed, and 82 (29%) patients died before transplantation.
TABLE 8. Summary of adverse events in all patients treated
with VE LVAS
Cause
Independent of cause Device related
Adverse event No. of patients % No. of patients %
Bleeding 133 48 31 11
Infection 125 45 113 40
Right heart failure 31 11 0 0
Renal dysfunction 158 56 0 0
Hepatic dysfunction 263 94 0 0
Neurologic dysfunction 75 27 14 5
Pulmonary dysfunction 5 2 0 0
Thromboembolic events 34 12 17 6
Mechanical failure 3 1 3 1
Death 82 29 3 1
TABLE 9. Improvement in NYHA functional status of
patients in release program (n = 160)*
At entry into release
NYHA functional class At VE LVAS implantation program
Class I 0 69
Class II 1 91
Class III 6 0
Class IV 153 0
*Median time from implantation to entry into release program = 35 days.
TABLE 10. Number of patients surviving to transplantation
Weeks
0–1 1–2 2–5 5–10 10–25 25–50
VE LVAS–treated patients 280 247 233 207 166 55
(n = 280)
Historical controls (n = 48) 48 17 13 6 0 0
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Thirty-two (67%) of 48 control patients died. Overall, as
shown by log-rank analysis, the probability of survival to
transplantation was significantly greater for the VE LVAS–
treated patients than for the controls (P = .0001) (Figure 2
and Table 10). In the first 7 days of the trial, 22 (46%) con-
trol patients died compared with 30 (11%) VE LVAS–
treated patients. 
Of the 10 treated patients who elected to have the device
removed, 5 had experienced myocardial recovery. Another
4 had the pump explanted because of infection and 1
because of a pump malfunction. The survival duration for
the 10 patients who underwent explantation ranged from 0
to 1358 days (Table 11), and the 1-year survival was 43%.
Post-transplantation survival. Post-transplantation sur-
vival significantly improved in VE LVAS–treated patients
compared with that in control patients (P = .0197) (Figure
3 and Table 12). The 1-year post-transplantation survival
was 84% (158/188) for VE LVAS–treated patients versus
63% (10/16) for controls.
Predictors of poor survival. Four factors were associated
with significantly poorer survival of VE LVAS–treated
patients: age, prior cardiac surgery, elevated baseline creati-
nine level, and elevated baseline total bilirubin level (Table
13).
Discussion
Despite improvements in medical therapy for heart failure,
such therapy is still of limited efficacy in patients with
advanced disease.10 This assessment is corroborated by the
dismal survival (33%) in our group of control patients with
end-stage disease who were not supported with an LVAS.
The only survivors in the control group were those who
Figure 2. Probability of survival to transplantation for VE LVAS–
treated versus control patients.
Figure 3. Probability of 1-year post-transplantation survival for VE
LVAS–treated versus control patients.
TABLE 11. Experience of 10 patients undergoing explantation
Patient Reason for explantation Outcome Postexplantation survival (d) Cause of death
1 Myocardial recovery Died 209 Heart failure
2 Myocardial recovery Died 1358 Heart failure
3 Infection Reimplantation, 175
transplantation, alive
4 Myocardial recovery Alive 1207
5 Myocardial recovery Died 160 Pancreatic cancer
6 Infection Alive 367
7 Infection Died 32 MSOF
8 Myocardial recovery Died 1021 Unknown
9 Pump malfunction Died 8 MSOF
10 Infection Died 0 Sepsis
MSOF, Multiple system organ failure.
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received a heart transplant. The median waiting time for the
patients who received a transplant was only 4 days. This
short waiting time would be impossible today, even after
aggressive medical therapy. Mechanical circulatory support
with subsequent transplantation thus appears to be the only
alternative for many patients with end-stage heart disease.
When the long-term limitations of heart transplantation (eg,
50% mortality at 10 years), limited donor availability (2000
donors yearly), and drug-related morbidity (eg, hyperten-
sion, renal dysfunction) are considered, the role of long-
term assist devices appears even more important.11-13
In the present study, the HeartMate VE LVAS provided
adequate hemodynamic support, had an acceptably low inci-
dence of adverse effects, and improved NYHA functional
class and survival in heart transplant candidates both inside
and outside the hospital. The best indicator of its safety and
efficacy in transplant candidates was the survival benefit it
conferred—both before and after transplantation. (A similar
post-transplantation survival benefit was also shown for the
HeartMate IP LVAS in its earlier clinical trial.) This benefit
can be attributed to the normalization of end-organ function
and return to NYHA class I function in the majority of
cases.14 Consequently, concerns over the negative immuno-
logic impact of using the VE LVAS as a bridge to transplanta-
tion (eg, an increase in reactive antibodies) are not warranted,
because the survival in this patient group was excellent with
no evidence of increased infection or rejection episodes.15
Another indicator of the VE LVAS device’s safety and
efficacy was the rate of adverse events in this study, which
mirrored the rate established in the earlier IP LVAS trial.2
Although to a certain extent our assignment of adverse events
to the device or to the patient in this study was subjective, it
represented an effort to distinguish between the 2 types of
causes and to assess the relative contribution of the device to
adverse events while still reporting their total incidence.
In the present study, organ dysfunction, seen in most
patients before implantation or immediately after implanta-
tion, was substantially corrected during LVAS support.
Although in most cases aspirin and dipyridamole were the
only antiplatelet agents used, the incidence of thromboem-
bolic events in the present trial was low and constituted one
of the major advantages of using the VE LVAS. On the other
hand, the incidence of bleeding was relatively high but not
surprisingly so in light of the severity of the disease and
expected development of coagulopathies.16,17 In present
clinical practice, this problem is apparently being reduced
by the more routine use of antifibrinolytic agents.17,18
Similarly, the incidence of infections, and especially drive-
line infections, was high; however, design modifications in
the VE LVAS, along with better timing of device placement,
might decrease infection rates in the future.19,20 Our pul-
monary dysfunction data were of limited value because
forced expiratory volume in 1 second was not measured in
all patients. The incidence of right heart failure and subse-
quent high mortality justifies the more routine use of nitric
oxide, prostaglandins, and phosphodiesterase inhibitors to
prevent this complication.21 Unfortunately, no data have
been collected on the incidence of right-sided dysfunction
and the subsequent need for prolonged use of intravenous
inotropic agents.
Another interesting finding of the present multicenter
trial, which followed the experiences of several single cen-
ters in the use of LVAS as a bridge to recovery,4,22 was the
outcome of patients who underwent elective device explan-
tation. Most previous findings have been limited to that sub-
set of patients being bridged to transplantation and therefore
not selected as candidates for recovery. Thus, as our under-
standing of end-stage myocardial disease and the processes
involved in recovery improves, so might the outcomes of
patients treated with the VE LVAS. In fact, experience
gained from the use of left ventricular assist devices as a
bridge to transplantation could be useful in selecting patients
with end-stage cardiac disease who would be good candi-
dates for implantation (ie, those at low risk for perioperative
complications and thus having a better chance of recovery).
The ultimate goal in developing ventricular assist sys-
tems is to create technology that will allow the transplant
candidate to lead a normal, active life while receiving
TABLE 12. Number of patients surviving after transplantation
Weeks after transplant
5 10 15 20 25 50
VE LVAS–treated patients (n = 188) 173 169 167 166 165 134
Historical controls (n = 16) 13 12 10 10 10 7
TABLE 13. Risk factors for poor survival to transplantation*
Variable Hazard ratio P value 95% CI
Age (range, 11-72 y) 1.03 .0163 1.01-1.05
Prior heart surgery 1.69 .0366 1.03-2.76
Baseline creatinine 1.38 .0005 1.15-1.65
(range, 0.4-8.9 mg/dL)
Baseline total bilirubin 1.08 .0043 1.03-1.14
(range, 0.1-23.0 mg/dL)
CI, Confidence interval.
*Data were analyzed by using the Cox proportional hazards model.
Predictor variables were selected for the model by means of a stepwise
technique. Variables evaluated for addition to the model included patient
age, prior heart surgery (either coronary artery bypass grafting or valve
surgery), sex, ischemic heart disease, baseline white blood cell count,
baseline infection, baseline blood urea nitrogen, baseline aspartate
aminotransferase, baseline alanine aminotransferase, baseline total biliru-
bin, baseline creatinine, prior myocardial infarction, and prior coronary
artery disease.
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mechanical circulatory support. The present multicenter
trial suggests that the VE LVAS improves the outcome of
patients with end-stage heart disease who are awaiting a
transplant, and it has defined a subset of patients who can-
not be supported by medical therapy. It also provides impor-
tant insights into any future application of this technology
for permanent use as heart replacement therapy (eg, the
REMATCH trial).23 Moreover, in the field of heart trans-
plantation, it is the only study with a control cohort (ie,
patients who did not have an LVAS implanted but otherwise
met all inclusion criteria) to show a survival benefit for
transplantation. This observation is especially important
since data on comparable groups of patients (eg, patients
with end-stage heart disease who fulfill criteria for left ven-
tricular assist device implantation) are hard to obtain now
owing to the ethical issues involved. We believe that the
control group we used is the best comparison group for
patients with terminal disease that we are likely to develop.
With better medical therapy, it is more difficult to deter-
mine the survival benefit of heart transplantation. In a
recent study of German heart transplant programs, Deng
and colleagues24 showed that a survival benefit was
achieved only in the sickest patients. However, that study
lacked a control cohort. In the present study, the patients
who were on the waiting list for a transplant and reached the
level of cardiac deterioration that would qualify them for
insertion of a HeartMate LVAS (either pneumatic or elec-
tric) achieved a survival benefit only after LVAS implanta-
tion and subsequent cardiac transplantation. Furthermore,
the survival benefit was much greater for those patients who
received the pump than for those who did not.
We thank Laura Damme, RN, and Allen Alexander, MD, for
their assistance in preparing the manuscript; Mr Jerry Heatley for
performing the statistical analyses required for this article; and the
Section of Scientific Publications at the Texas Heart Institute for
editorial assistance. 
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